Top Story

IMPACT: No difference in number of injections with or without squalamine lactate for wet AMD

March 30, 2015

No meaningful difference was found in mean number of injections of squalamine lactate ophthalmic solution combined with Lucentis compared with Lucentis monotherapy for treatment of wet age-related macular degeneration, according to topline results of the IMPACT study released by Ohr Pharmaceutical.

Mean number of injections was the primary endpoint in the phase 2 study, a 9-month clinical trial evaluating the safety and efficacy of OHR-102 (0.2% squalamine lactate ophthalmic solution) plus as-needed Lucentis (ranibizumab, Genentech) combination therapy for neovascular AMD.

Breaking News

FDA accepts investigational new drug application for phase 2 trial of NT-503 encapsulated cell therapy

March 30, 2015
The FDA has accepted an investigational new drug application for a phase 2 clinical study of NT-503 encapsulated cell therapy for the treatment of recurrent subfoveal…
Darrell White Blog

BLOG: Dry eye syndrome business news from Caribbean Eye

March 30, 2015
Even if you are not actively in the market to buy anything new when you go to a meeting or convention, no matter now big or small, it’s always worth the effort to spend…
thumbnail for video 4138719116001 Meeting News CoverageVideo

VIDEO: Emerging therapies for diabetic macular edema

March 30, 2015
Peter K. Kaiser, MD, highlights emerging new classes of treatment for retinal eye diseases and diabetic macular edema at Retina 2015.
thumbnail for video 4138769948001 Meeting News CoverageVideo

VIDEO: Ocular allergic disease therapeutic update

March 29, 2015
Jodi Luchs, MD, FACS, discusses the proper diagnosis in patients with ocular allergies at Hawaiian Eye 2015.
More News Headlines »
Practical Retina

Comparing Aflibercept, Bevacizumab, and Ranibizumab for DME: Analysis of DRCR Protocol T

Ophthalmic Surgery, Lasers and Imaging Retina
Online Advanced Release, March 5, 2015
More »
CME
Ocular Surface Disease in the Surgical Setting

Ocular Surface Disease in the Surgical Setting: Recognition and Treatment of an Increasing Dilemma

This activity is supported by an educational grant from Allergan, Inc.

Dry eye disease (DED) is becoming an increasing burden as the population ages or undergoes treatments, procedures, or…
More »
Meeting News Coverage Video
thumbnail for video 4138769948001

VIDEO: Ocular allergic disease therapeutic update

March 29, 2015
Jodi Luchs, MD, FACS, discusses the proper diagnosis in patients with ocular allergies at Hawaiian Eye 2015.
More »
morganatic-roan